The outstanding physio-pathological role played by integrin receptors in living subjects motivates the enormous interest shown by scientists worldwide for this topic. More than twenty years of research has spanned across the structural and functional elucidation of these proteins and over their antagonism-based biomedical applications. The proof-of concept stage, aimed at identifying potent inhibitors, covered a decade of studies, and paved the way for a more advanced era of research where these antagonist molecules were thrown into the deep end of applicative studies. This review intends to summarize the major efforts conducted thus far and focuses on the design, synthesis and biomedical applications of cyclic RGD-containing alphaVbeta3 integrin antagonists, in both their small and macromolecular formats. In particular, Chapters 1and 2 offer a comprehensive outlook on the rational basis for the design of integrin inhibitors, Chapter 3 chronicles the biological and medical applications of monofunctional RGD integrin ligands both in their monomeric and multimeric asset, and Chapter 4 illustrates the potential of RGD-based multifunctional systems in molecular medicine.

Targeting alphaVbeta3 Integrin: Design and Applications of Mono- and Multifunctional RGD-Based Peptides and Semipeptides / Auzzas, L.; Zanardi, Franca; Battistini, Lucia; Burreddu, P.; Carta, P.; Rassu, G.; Curti, Claudio; Casiraghi, Giovanni. - In: CURRENT MEDICINAL CHEMISTRY. - ISSN 0929-8673. - 17:(2010), pp. 1255-1299.

Targeting alphaVbeta3 Integrin: Design and Applications of Mono- and Multifunctional RGD-Based Peptides and Semipeptides

ZANARDI, Franca;BATTISTINI, Lucia;CURTI, Claudio;CASIRAGHI, Giovanni
2010-01-01

Abstract

The outstanding physio-pathological role played by integrin receptors in living subjects motivates the enormous interest shown by scientists worldwide for this topic. More than twenty years of research has spanned across the structural and functional elucidation of these proteins and over their antagonism-based biomedical applications. The proof-of concept stage, aimed at identifying potent inhibitors, covered a decade of studies, and paved the way for a more advanced era of research where these antagonist molecules were thrown into the deep end of applicative studies. This review intends to summarize the major efforts conducted thus far and focuses on the design, synthesis and biomedical applications of cyclic RGD-containing alphaVbeta3 integrin antagonists, in both their small and macromolecular formats. In particular, Chapters 1and 2 offer a comprehensive outlook on the rational basis for the design of integrin inhibitors, Chapter 3 chronicles the biological and medical applications of monofunctional RGD integrin ligands both in their monomeric and multimeric asset, and Chapter 4 illustrates the potential of RGD-based multifunctional systems in molecular medicine.
2010
Targeting alphaVbeta3 Integrin: Design and Applications of Mono- and Multifunctional RGD-Based Peptides and Semipeptides / Auzzas, L.; Zanardi, Franca; Battistini, Lucia; Burreddu, P.; Carta, P.; Rassu, G.; Curti, Claudio; Casiraghi, Giovanni. - In: CURRENT MEDICINAL CHEMISTRY. - ISSN 0929-8673. - 17:(2010), pp. 1255-1299.
File in questo prodotto:
File Dimensione Formato  
2010_Auzzas_CurrMedChem_abs.pdf

non disponibili

Tipologia: Abstract
Licenza: Creative commons
Dimensione 19.37 kB
Formato Adobe PDF
19.37 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
2010_Auzzas_CurrMedChem_Targeting.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: Creative commons
Dimensione 1.75 MB
Formato Adobe PDF
1.75 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2301628
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 93
  • ???jsp.display-item.citation.isi??? 90
social impact